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Abstract
The membrane proteins mediating the ATP-dependent transport of lipophilic substances conjugated to glutathione,
glucuronate, or sulfate have been identified as members of the multidrug resistance protein (MRP) family. Several isoforms
of these conjugate export pumps with different kinetic properties and domain-specific localization in polarized human cells
have been cloned and characterized. Orthologs of the human MRP isoforms have been detected in many different organisms.
Studies in mutant rats lacking the apical isoform MRP2 (symbol ABCC2) indicate that anionic conjugates of endogenous
and exogenous substances cannot exit from cells at a sufficient rate unless an export pump of the MRP family is present in
the plasma membrane. Several mutations in the human MRP2 gene have been identified which lead to the absence of the
MRP2 protein from the hepatocyte canalicular membrane and to the conjugated hyperbilirubinemia of Dubin^Johnson
syndrome. Overexpression of recombinant MRP2 confers resistance to multiple chemotherapeutic agents. Because of its
function in the terminal excretion of cytotoxic and carcinogenic substances, MRP2 as well as other members of the MRP
family, play an important role in detoxification and chemoprevention. ß 1999 Elsevier Science B.V. All rights reserved.
Keywords: ATP-dependent transport; Dubin^Johnson syndrome; Green £uorescent protein; Leukotriene C4 ; MRP1,2,3; Multidrug
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1. Introduction
The membrane proteins mediating the ATP-de-
pendent unidirectional transport of conjugates of
lipophilic substances with glutathione, glucuronate,
or sulfate have been recognized as members of the
multidrug resistance protein (MRP) family [1^12]. In
addition to many anionic conjugates [13], a number
of unconjugated amphiphilic anions can serve as sub-
strates for MRP1, MRP2, and possibly for addition-
al members of the MRP family of transport proteins
[14^18]. Prior to the elucidation of the transport
function of MRP1 in 1994 [1^3,19], ATP-dependent
transport of conjugates was characterized by use of
inside-out plasma membrane vesicles from many cell
types including erythrocytes [20,21], hepatocytes [22^
24], heart [25], and mastocytoma cells [26]. It has
become apparent that anionic conjugates of endoge-
nous and exogenous substances cannot exit from
cells into the extracellular space at a su⁄cient rate
unless a MRP-type transporter is present in the plas-
ma membrane (Fig. 1). This is exempli¢ed by studies
in mutant rats selectively lacking the MRP2 protein
in the hepatocyte canalicular membrane [27^30].
These mutant animals cannot release the endogenous
glutathione S-conjugate leukotriene C4 (LTC4) and
its metabolites across the hepatocyte canalicular
membrane into bile [31,32]. This leads to an accumu-
lation of the conjugates within the hepatocytes and
to their subsequent exit across the basolateral mem-
brane into blood [32] in a transport step probably
mediated by MRP3 [33]. Finally, the LTC4 metabo-
lites undergo renal elimination into the urine [31,32].
The localization of MRP2 in the apical membrane
of polarized epithelia [27^29,34,35] favors a particu-
lar role of this MRP isoform in detoxi¢cation by the
terminal excretion of conjugation products of drug
metabolism into bile or urine (Fig. 1). Moreover,
since both MRP2 and MRP1 export oxidized gluta-
thione [36], these MRP family members contribute to
the control of the GSSG/GSH ratio and to the de-
fense against oxidative stress under conditions of en-
hanced GSSG formation. In cancer chemotherapy,
MRP1 [37,38], MRP2 [8], and MRP3 [39] have the
capacity to confer resistance to chemotherapeutic
agents. Thus, knowledge of the substrate speci¢city,
the expression level, the plasma membrane domain-
speci¢c localization, and the cell type-speci¢c expres-
sion of the MRP isoforms contributes to our under-
standing of detoxi¢cation pathways and drug resis-
tance mechanisms, and suggests approaches to the
development of inhibitors interfering with MRP-
mediated export of cytotoxic agents and drugs.
2. The MRP family of conjugate export pumps
ABC transporters belonging to the MRP family
and mediating the export of anionic conjugates out
of cells have been identi¢ed in a variety of di¡erent
organisms including yeast, nematodes, and plants
[12,40,41] (Table 1). The family of the human multi-
drug resistance proteins (MRPs) consists of at least
six members known as MRP1 (symbol ABCC1),
MRP2 (ABCC2; also known as cMRP or cMOAT),
and the more recently identi¢ed family members
MRP3, MRP4, MRP5, and MRP6 (ABCC3,
ABCC4, ABCC5, and ABCC6 [44,45]). The deduced
amino acid sequence lengths range from 1325 amino
acids for MRP4 to 1545 amino acids for MRP2. The
membrane topology, predicted by several computa-
tional methods, is a notable feature common to at
least four of the six members. In contrast to the
typical six plus six transmembrane segment organi-
zation described for the members of the P-glycopro-
tein family [46,47], the MRPs exhibit an additional
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amino-proximal membrane-spanning domain repre-
sented by an extension of approximately 200 amino
acids [48]. This membrane topology distinguishes the
MRP family from other ABC-transporters [48]. Best
characterized members of the MRP family are the
founding member MRP1 [49] and the apically local-
ized member MRP2 [29,50]. MRP1 was cloned from
a drug-selected human lung cancer cell line and con-
sists of 1531 amino acids. The MRP1 gene, located
on chromosome 16p13.12^13, spans approximately
200 kb and contains 31 exons and a high proportion
of class 0 introns [51]. Elucidation of the sequence
[49] and the function [1,2] of MRP1 suggested the
presence of functionally related transporters in other
tissues. Comparison of transport characteristics ob-
tained with normal rat liver canalicular membrane
vesicles and vesicles from GY/TR3 and EHBR mu-
tant rat strain livers resulted in the characterization
and identi¢cation of MRP2 (cMRP, cMOAT), the
apical isoform of MRP1 [27^29]. This protein is
mainly localized to the canalicular membrane of hep-
atocytes [27,29] and, in addition, in several other
apical membrane domains including the apical mem-
brane of kidney proximal tubule epithelia [34,35].
Immuno£uorescence studies demonstrated, that the
MRP2 protein is absent in livers of GY/TR3 [27^
29] and EHBR rats [29,30] and in the liver of patients
with Dubin^Johnson syndrome [52,53].
The close relationship between MRP1 and MRP2
is also evident from the comparison of the topology
of both transporters. Several methods have been
used to predict the transmembrane organization of
human MRP1 and MRP2. These methods include
computational analyses, mutational analyses and
limited proteolysis experiments [54], as well as epi-
tope insertion studies [55^57]. Most studies focused
on the topology prediction of MRP1, but several
hydrophobicity and transmembrane predicting pro-
grams, such as the transmembrane analysis program
(TMAP) [58], demonstrated the close topological re-
lationship of MRP1 and MRP2. Both transporters
are predicted to consist of a MDR-like core structure
of two transmembrane regions and two ATP-binding
domains and, in addition, of a large third amino-
proximal transmembrane region. A remarkable topo-
logical feature of both proteins was found in studies
Fig. 1. Uptake, biotransformation, and MRP-mediated export of endogenous substances, drugs, and carcinogens.
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on the localization of the amino terminus. The amino
terminus was predicted to be extracytosolic since
most predictions favored an odd number of trans-
membrane domains. This was described ¢rst for
MRP2 on the basis of TMAP analyses [29], and sub-
sequently established by epitope insertion experi-
ments, performed on MRP1 [59] and by immuno-
£uorescence studies for MRP2 [8]. These studies
demonstrate experimentally the extracellular location
of the amino terminus. Elucidation of structural fea-
tures, genomic organization, and transport properties
of MRP1 and MRP2 provided a basis for the com-
parison with additional members of this family.
The identi¢cation of MRP3, MRP4, and MRP5
was mainly based on expressed sequence tags (EST)
database analyses [44] followed by the cloning of
cDNA fragments [45]. All three proteins are encoded
by di¡erent genes located on di¡erent chromosomes,
MRP3 on chromosome 17q21.3, MRP4 on chromo-
some 13q31^32, and MRP5 on chromosome 3q27
[45]. Among these, MRP3 is best characterized with
respect to its localization and in part with respect to
its transport function [9,33,39]. The tissue expression
pattern of MRP3 exhibits similarities with the tissue
distribution of MRP2. Both proteins are highly ex-
pressed in liver and colon and on a lower level in
kidney as demonstrated by Northern blotting [33].
MRP3 was localized exclusively to the basolateral
membrane of hepatocytes as studied by immuno-
£uorescence microscopy [33,39]. A comparison of
MRP3 mRNA expression in normal rat liver and
liver from bile duct-ligated or MRP2-de¢cient GY/
TR3 and EHBR mutant rats demonstrated that
MRP3 is expressed at a low level under normal con-
ditions but upregulated under conditions when the
canalicular secretion of conjugates is impaired [9].
This upregulation of MRP3 was also observed in
studies on the protein expression in human liver.
Table 1
Amino acid sequence identity of human MRP2 with related transporters of the MRP family
Species Protein Symbol AA Identity (%) Accession number Conjugate export
Human MRP1 ABCC1 1531 48 NM_004996 ++
MRP2 ABCC2 1545 100 FX96395 ++
MRP3 ABCC3 1527 46 Y17151 ++
MRP4 ABCC4 1325 37 AF071202
MRP5 ABCC5 1437 35 AF104942 ++
MRP6 ABCC6 1503 38 AF076622
CFTR ABCC7 1480 27 P13569
SUR ABCC8 1581 30 U63421
Rabbit MRP2 1564 82 Z49144 ++
Rat MRP2 1541 78 X96393 ++
MRP3 1523 46 AB010467 ++
MRP6 1502 36 AB010466
Mouse MRP1 1528 48 AF022908 ++
MRP5 1436 35 AB019003
Caenorhabditis elegans MRP1 1540 42 U66260 +
MRP2 1525 42 U66261 +
Arabidopsis thaliana MRP1 1622 36 AF008124 ++
MRP2 1623 35 AF020288 ++
MRP3 1515 33 U92650 ++
MRP4 1516 35 AJ002584 +
MRP5 1514 32 U11250
Yeast YDR135C 1515 39 L35237 ++
YLL015W 1559 34 Z73120
Amino acid sequence identities are given in relation to human MRP2 (boldface). Transporters for which the conjugate transport func-
tion has been shown directly are indicated by ++, transporters for which the conjugate export has been demonstrated indirectly, e.g.
by determination of toxin resistance, are indicated by +. Computer analysis was performed using tree alignment from Husar program
[42] based on the Wisconsin Genetics Computer Group program package [43].
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Liver from a patient with Dubin^Johnson syndrome
and liver from a patient with primary biliary cirrho-
sis exhibited a strong MRP3 expression in the baso-
lateral hepatocyte membrane when compared with
apparently normal liver [33]. MRP3 may serve as
an over£ow mechanism mediating the export of con-
jugates across the basolateral membrane under con-
ditions when the canalicular secretion of MRP2 sub-
strates is impaired. The genomic organization of
MRP3 has been studied in part [60] and revealed
similarities to the known genomic structures of hu-
man MRP1 [51] and MRP2 [53] as indicated by
many identical splice junction sites on amino acid
level.
Little is presently known about localization and
transport characteristics from MRP4, MRP5, and
MRP6. MRP6 was ¢rst reported to be a short,
MRP-related protein with only one nucleotide bind-
ing fold. The protein was cloned from anthracycline-
selected cells [61] and was thus called ARA (anthra-
cycline resistance-associated). Further analyses sug-
gested that this short MRP isoform is a cell selection
or cloning artefact and that ARA is in fact the car-
boxyl terminal half of human MRP6 [62]. The
MRP6 gene is located on chromosome 16 next to
the MRP1 gene with which it is coampli¢ed during
overexpression [62].
3. Substrates and kinetic properties of MRP1, MRP2,
and MRP3
Following the demonstration in 1994 that MRP1
functions as an unidirectional ATP-dependent export
pump for the endogenous glutathione S-conjugate
leukotriene C4 [1^3], the substrate speci¢city of this
transport protein was studied intensively using in-
side-out membrane vesicles from cells expressing
the recombinant protein at a high level [4^6,36,63^
71]. The substrate spectrum comprises amphiphilic
anions, particularly conjugates of lipophilic com-
pounds with glutathione, glucuronate, or sulfate,
including cysteinyl leukotrienes, bilirubin glucurono-
sides, 17L-glucuronosyl estradiol, and sulfatolitho-
cholyl-taurine as endogenous compounds (Table 2).
The glutathione S-conjugate leukotriene C4 is the
substrate with the highest a⁄nity identi¢ed so far
(Km value 0.1 WM). Glutathione disul¢de is also
transported by MRP1, however, with a relatively
low a⁄nity (Km value 100 WM) [36], indicating a
role of this export pump in oxidative stress associ-
ated with increasing concentrations of glutathione
disul¢de. MRP1-mediated ATP-dependent transport
of reduced glutathione was not detectable in these
studies with isolated membrane vesicles [36]. How-
ever, reduced glutathione can serve as a cosubstrate
with neutral or cationic substances. This is indicated
by the ATP-dependent transport of the cytostatic
drugs vincristine and daunorubicin in the presence
of reduced glutathione [6,65,71]. Both drugs are
also substrates for MDR1 P-glycoprotein, which, in
contrast to MRP1, transports these compounds un-
modi¢ed and independently of glutathione [47]. For
some cytostatic drugs (Table 2) their glutathione and
glucuronate conjugates have been identi¢ed as
MRP1 substrates. The anionic drug methotrexate
was identi¢ed as a cytostatic agent transported in
its native form [70]. This transport of drugs is in
line with the multidrug resistance conferred by
MRP1. In addition to methotrexate, several addi-
tional amphiphilic organic anions which are not con-
jugated have been shown to be transported by MRP1
directly as exempli¢ed by the penta-anionic £uores-
cent dye Fluo-3 taken up into inside-out membrane
vesicles [16,18].
The spectrum of substrates for MRP1 is similar to
that of the ATP-dependent hepatocyte canalicular
conjugate export pump functionally known for
many years [22,24,75] and molecularly identi¢ed as
MRP2 [27^30,50]. Previously, ATP-dependent trans-
port measurements into inside-out hepatocyte canal-
icular membrane vesicles from normal rats in com-
parison with vesicles from GY/TR3 and EHBR
mutant rats selectively lacking MRP2 [27,29] have
been valuable in estimating the substrate speci¢city
of this transport protein [24,75,77,89], which is sim-
ilar to that of MRP1 (Table 2). The availability of
cell lines stably expressing the recombinant protein
enabled the characterization of the substrate speci¢c-
ity of human and rat MRP2 under de¢ned condi-
tions [7,8,10,74] and to identify kinetic di¡erences
between MRP2 and MRP1 [8]. MRP1 exhibits a
10-fold higher a⁄nity to leukotriene C4 and a 5-
fold higher a⁄nity to 17L-glucuronosyl estradiol in
comparison to MRP2 (see Km values Table 2) [8]
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Table 2
Substrates for MRP1, MRP2, and MRP3
Substrate Km value (WM) References
MRP1 (human, recombinant)
Leukotriene C4 0.1 [2,5,67]
Leukotriene D4 [2,4]
Leukotriene E4 [2,4]
N-Acetyl-leukotriene E4 [4]
S-Glutathionyl a£atoxin B1 0.2 [64]
S-Glutathionyl 2,4-dinitrobenzene (DNP-SG) 3.6 [4]
S-Glutathionyl prostaglandin A2 [68]
S-Glutathionyl ethacrynic acid 28 [66]
S-Glutathionyl N-ethylmaleimide [72]
Chlorambucil
^ monochloro-monoglutathionyl [69]
^ monohydroxy-monoglutathionyl [69]
^ bisglutathionyl [69]
Melphalan
^ monochloro-monoglutathionyl [4,69]
^ monohydroxy-monoglutathionyl [69]
Glutathione disul¢de 93 [36]
Bilirubin
^ monoglucuronosyl [63]
^ bisglucuronosyl [63]
17L-Glucuronosyl estradiol 1.5 [4]
2.5 [6]
2.9 [67]
6K-Glucuronosyl hyodeoxycholate [4]
Glucuronosyl etoposide [4]
3K-Sulfatolithocholyltaurine [4]
Chlorambucil [69]
Folate [13]
Methotrexate 50 [70] Leier et al., 1999a
Fluo-3 12 [18]
p-Aminohippurate 372 Leier et al., 1999a
Vincristine+reduced glutathione [5,65,67,71]
Daunorubicin+reduced glutathione [71]
A£atoxin B1+reduced glutathione [64]
MRP2 (human, recombinant)
Leukotriene C4 1.0 [8]
S-Glutathionyl 2,4-dinitrobenzene (DNP-SG) 6.5 [7]
70 [73]
S-Glutathionyl ethacrynic acid [7]
Bilirubin
^ monoglucuronosyl 0.7 [74]
^ bisglucuronosyl 0.9 [74]
17L-Glucuronosyl estradiol 7.2 [8]
Methotrexate [70]
p-Aminohippurate 880 Leier et al., 1999a
Ochratoxin A Leier et al., 1999a
MRP2 (rat, recombinant)
Leukotriene C4 1.1 [8,10]
S-Glutathionyl 2,4-dinitrobenzene (DNP-SG) 0.2 [10]
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Table 2 (continued)
Substrate Km value (WM) References
Bilirubin
^ monoglucuronosyl 0.8 [74]
^ bisglucuronosyl 0.5 [74]
17L-Glucuronosyl estradiol 6.9 [8]
MRP2 (rat; normal/mutant BCM)
Leukotriene C4 0.3 [24]
Leukotriene D4 1.5 [24]
Leukotriene E4 [24]
N-Acetyl leukotriene E4 5.2 [24]
S-Glutathionyl 2,4-dinitrobenzene (DNP-SG) 18 [76]
S-Glutathionyl sulfobromophthalein [77]
Glutathione disul¢de [75,78]
Bilirubin
^ monoglucuronosyl [63]
^ bisglucuronosyl [63,78]
Glucuronosyl nafenopin [79]
Glucuronosyl E3040 5.7 [76]
Glucuronosyl grepa£oxacin 7.2 [80]
Glucuronosyl SN38 carboxylate [81]
Glucuronosyl SN38 lactone [81]
SN38 carboxylate [81]
CPT11 carboxylate [81]
Sulfobromophthalein 31 [82]
Fluo-3 3.7 [16]
5-Methyltetrahydrofolate 126 [83]
Methotrexate 295 [84]
Temocaprilat 93 [85]
Pravastatin 220 [86]
BQ123 98 [87,88]
BQ485 6.5 [88]
BQ518 15 [88]
MRP3 (human, recombinant)
Bilirubin
^ monoglucuronosyl Kamisako et al., 1999a
MRP3 (rat, recombinant)
Leukotriene C4 [9]
S-Glutathionyl 2,4-dinitrobenzene (DNP-SG) [9]
17L-Glucuronosyl estradiol 67 [9]
Glucuronosyl E3040 [9]
Methotrexate [9]
Compounds listed have been identi¢ed as substrates by measurements of the ATP-dependent transport into inside-out membrane
vesicles from cells expressing the respective recombinant multidrug resistance protein in comparison to membrane vesicles from control
vector-transfected cells. In addition, measurements of the ATP-dependent transport into hepatocyte canalicular membranes vesicles
from MRP2-de¢cient mutant rats (GY/TR3 and EHBR) [28,29] in comparison to those from normal rats are presented.
BCM, bile (hepatocyte) canalicular membranes; BQ123, cyclic pentapeptide, endothelin antagonist (cyclo[D-Trp-D-Asp-L-Pro-D-Val-L-
Leu]) ; BQ485, linear peptide (perhydroazepino-N-carbonyl-L-Leu-D-Trp-D-Trp); BQ518, (cyclo[D-Trp-D-Asp-L-Pro-D-Thg-L-Leu]) ;
CPT11, irinotecan (7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxycamptothecin) ; E3040, 6-hydroxy-5,7-dimethyl-2-methylamino-
4-(3-pyridylmethyl)benzothiazole ; Fluo-3, 1-[2-amino-5-(2,7-dichloro-6-hydroxy-3-oxo-3H-xanthen-9-yl)]-2-(2P-amino-5P-methyl-phen-
oxy)-ethane-N,N,NP,NP-tetraacetic acid penta ammonium salt; 5-methyltetrahydrofolate, 5-methyl-tetrahydropteridinyl L-glutamic acid;
SN38, de-esteri¢ed metabolite of CPT11 (7-ethyl-10-hydroxycamptothecin); temocaprilat, pharmacologically active metabolite of temo-
capril hydrochloride, prodrug of angiotensin-converting enzyme inhibitor (K-(2S,6R)-6-[(1S)-1-ethoxy-carbonyl-3-phenyl-propyl]amino-
5-oxo-2-(2-thienyl)perhydro-1,4-thiazepin-4-yl acetic acid hydrochloride).
aUnpublished data.
BBAMEM 77715 19-11-99 Cyaan Magenta Geel Zwart
J. Ko«nig et al. / Biochimica et Biophysica Acta 1461 (1999) 377^394 383
whereas bilirubin glucuronosides are preferentially
transported by MRP2 [63,74].
MRP3, which exhibits a similar tissue distribution
as MRP2, but is localized to the basolateral mem-
brane domain of polarized cells [33,39], has been also
shown to function as a conjugate export pump [9].
Studies with membrane vesicles from cells expressing
recombinant rat MRP3 suggested a preference for
glucuronosides and a low a⁄nity for leukotriene C4
[9]. However, the Km value for 17L-glucuronosyl es-
tradiol (Table 2) was almost 10-fold higher than that
for MRP2. This may re£ect the function of MRP3 as
a basolateral over£ow system in hepatocytes ensur-
ing the elimination of compounds under conditions
of impaired canalicular MRP2-mediated secretion.
In addition to the elucidation of the substrate spe-
ci¢city, the identi¢cation of potent and speci¢c inhib-
itors of MRP-mediated transport is of importance
for the characterization of the transport function as
well as for the development of modulators of multi-
drug resistance mediated by MRP transporters. The
most potent inhibitors reported so far and tested for
inhibition of ATP-dependent MRP1-mediated trans-
port in isolated membrane vesicles are structural ana-
logs of the cysteinyl leukotrienes (summarized in [13]
and [90]). For example, the LTD4 analog MK571, a
monoanionic quinoline derivative developed as a
LTD4 receptor antagonist, was shown to inhibit
MRP1-mediated transport competitively in sub-mi-
cromolar concentrations [1,2,4,36]. This compound
also inhibits MRP2-mediated transport, although
with lesser potency [29]. A structural analog of leu-
kotriene C4, S-decylglutathione, also acts as a potent
competitive inhibitor of MRP1-mediated transport
[6]. Cyclosporin A and the non-immunosuppressive
cyclosporin A derivative PSC 833, which are both
known to inhibit several ATP-dependent export
pumps at low concentration [91], are relatively
weak inhibitors of MRP1- [2] and MRP2-mediated
transport [74]. The Ki value of cyclosporin A was
5 WM in human MRP1-mediated leukotriene C4
transport [2] and 21 WM in human MRP2-mediated
transport of monoglucuronosyl bilirubin [74]. Com-
pounds suggested as inhibitors on the basis of their
e¡ect on drug accumulation or on resistance reversal
in MRP1-overexpressing cells include the tyrosine
kinase inhibitor genistein [92], the bisindolylmalei-
mide protein kinase C inhibitor GF109203X [93],
and the quinolone di£oxacin [94]. An overview on
inhibitors of MRP1-mediated transport has been
published recently [90].
4. Drug resistance conferred by the apical conjugate
export pump MRP2
MRP1 when overexpressed in cells confers resis-
tance to many di¡erent antitumor drugs (reviewed
in [37]). MRP2 and MRP1 share a similar substrate
spectrum despite di¡erences in cellular localization
and kinetic properties [8,13]. This has suggested
that MRP2 may also confer drug resistance by
pumping drug conjugates or drug complexes with
glutathione out of the cell. Northern blot analyses
and RNase protection assays provided the ¢rst indi-
cations that MRP2 expression may correlate with
multidrug resistance [45,50,95]. MRP2 cDNA was
cloned initially from rat liver [27^29], in addition
human MRP2 cDNA was cloned from liver [29,96]
and from cisplatin-resistant human cancer cell lines
KB-CDP4 and P-CDP5 [50]. In both drug-resistant
cell lines MRP2 mRNA was overexpressed in com-
C
Fig. 2. Confocal laser scanning micrographs of MRP isoforms stably expressed in polarized MDCK cells using isoform-speci¢c anti-
bodies (green £uorescence in A^G), and £uorescence micrographs of MRP2, C-terminally tagged with GFP, and GFP alone in live,
polarized HepG2 cells (green £uorescence in H,I). Nuclei were stained with either propidium iodide (red £uorescence in A^F) or
Hoechst 33258 (blue £uorescence in H,I). (A,C,E) xy-planes and (B,D,F) corresponding optical vertical sections (xz-planes) are shown.
(A,B) Human MRP1 was detected with the MRP1-speci¢c QCRL1 antibody [55]. (C,D) MDCK cells expressing human MRP2 were
stained with an antibody directed against the carboxyl terminus (EAG) [8,29,63]. (E,F) Localization of human MRP3 in MDCK cells
was visualized with an antibody directed against the carboxyl terminus of the MRP3 isoform (FDS) [33]. (G) Non-permeabilized
MDCK cells expressing rat MRP2 were stained with the MDK antibody directed against the amino terminus of rat MRP2 demon-
strating the extracellular location of the amino terminus [8]. (H,I) Live, polarized HepG2 cells form apical vacuoles between adjacent
cells (asterisks). (H) MRP2-GFP localized to the apical membrane and, additionally, to intracellular vesicular structures. (I) GFP
alone was expressed throughout the cell, including the cytoplasm and the nucleus, but excluding apical vacuoles. Scale bars: 10 Wm.
BBAMEM 77715 19-11-99 Cyaan Magenta Geel Zwart
J. Ko«nig et al. / Biochimica et Biophysica Acta 1461 (1999) 377^394384
BBAMEM 77715 19-11-99 Cyaan Magenta Geel Zwart
J. Ko«nig et al. / Biochimica et Biophysica Acta 1461 (1999) 377^394 385
parison to non-resistant parental cell lines. A corre-
lation between MRP2 expression and cisplatin-resis-
tance was also demonstrated for several additional
cell lines by RNase protection assays and Northern
blot analyses [45,95]. Moreover, antisense cDNA was
used to reduce the expression of MRP2 protein in the
human hepatoma cell line HepG2 [97]. Upon trans-
fection of the antisense MRP2 cDNA HepG2 cells
showed elevated intracellular glutathione levels and
enhanced sensitivity to antitumor drugs including cis-
platin, vincristine, doxorubicin, and the camptothe-
cin derivatives CPT11 and SN38, but not to etopo-
side, 3-[4-amino-2-methyl-5-pyrimidinyl)methyl]-1-(2-
chloroethyl)-1-nitrosourea (ACNU), 5-£uorouracil,
and mitomycin C [97]. Direct evidence for MRP2-
mediated multidrug resistance [8] as well as resistance
to antifolates [70] was obtained from transfection
studies with MRP2 cDNA. A prerequisite for meas-
uring drug resistance mediated by MRP2 is the plas-
ma membrane localization of MRP2 in transfected
cells. Both in MDCKII cells and in HEK293 cells
recombinant MRP2 was localized to the plasma
membrane, though a large proportion of recombi-
nant MRP2 was also found intracellularly in
HEK293 transfectants [8]. Expression of both human
and rat MRP2 in MDCKII cells confers signi¢cant
resistance to etoposide and vincristine (Table 3). In
transfected HEK293 cells recombinant human
MRP2 confers resistance to etoposide, cisplatin, epi-
rubicin, and doxorubicin (Table 4). The mechanism
of MRP2-conferred resistance to these drugs is still
under investigation. One may expect that the same
mechanisms are involved as shown earlier for MRP1
[65,71]. MRP2 as well as MRP1 were also shown to
confer resistance to the antifolate methotrexate, a
substrate for MRP1 and MRP2, in transfected hu-
man ovarian carcinoma 2008 cells [70]. Clinical rele-
vance of MRP2-mediated drug resistance has been
emphasized by the ¢nding that MRP2 was detected
in 95% renal clear-cell carcinomas both at the
mRNA and at the protein level [35]. MRP2 expres-
sion was also detected by RT-PCR, immunoblotting,
and immuno£uorescence microscopy in lung, gastric,
and colorectal cancer cells, and in hepatocellular car-
cinomas ([98]; Nies et al., unpublished). Taken to-
gether, overexpression of MRP2 was found in di¡er-
ent epithelial malignant tumors and may contribute
to their resistance to antitumor drugs.
5. Expression and localization of MRP2 in polarized
cells
5.1. Immuno£uorescence localization of MRP
isoforms in polarized cells
Antibodies of high a⁄nity and selectivity have
been useful for the identi¢cation and localization of
individual MRP isoforms in di¡erent cell types. The
isoforms MRP1, MRP2, and MRP3 have related
functions, but di¡er in their membrane localization.
Studies on the domain-speci¢c sorting of individual
isoforms have become possible by the permanent ex-
pression of the respective recombinant MRP isoform
in polarized cells (Fig. 2).
MRP2 is the apical MRP isoform and is localized
to the canalicular membrane of rat and human hep-
atocytes [29,96,99,100], as well as to the apical mem-
Table 4
MRP2-mediated resistance to antitumor drugs in transfected
HEK293 cells
HEK-Co HEK-MRP2 human
IC50 IC50 RR
Cisplatin (WM) 2.4 24 10.0a
Etoposide (WM) 0.3 1.2 4.0a
Doxorubicin (nM) 44 346 7.8a
Epirubicin (nM) 3.8 19 5.0a
aP6 0.01. Sensitivity to antitumor drugs was determined by the
MTT cell viability assay. The relative resistance factor (RR)
was calculated by dividing the IC50 value of cells transfected
with human MRP2 (HEK-MRP2) by the IC50 value of cells
transfected with control vector (HEK-Co). Modi¢ed from [8].
Table 3
MRP2-mediated resistance to etoposide and vincristine in trans-
fected MDCKII cells
Etoposide Vincristine
IC50 (WM) RR IC50 (WM) RR
MDCK-Co 163 1.0 8.2 1.0
MDCK-MRP2 human 612 3.8a 49 6.0a
MDCK-MRP2 rat 809 5.0a 19 2.3a
aP6 0.01. Sensitivity to etoposide and vincristine was deter-
mined by the MTT cell viability assay. The relative resistance
factor (RR) was calculated by dividing the IC50 value of cells
transfected with rat or human MRP2 by the IC50 value of cells
transfected with control vector (MDCK-Co). Modi¢ed from [8].
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brane of rat hepatoma cells [16]. MRP2 expression
has also been shown by immunoblotting in mouse
[101] and rabbit liver [102], and in human hepatoma
HepG2 cells [63]. In addition to liver, MRP2 mRNA
was detected by Northern blotting in kidney, duode-
num and ileum [28,30]. Moreover, MRP2 expression
in human colon-derived Caco-2 cells was shown by
immunoblotting [103]. Furthermore, the apical local-
ization of MRP2 was demonstrated in rat and hu-
man kidney proximal tubules [34,35]. After transfec-
tion, rat [8] and human [7,8] MRP2 localized to the
apical membrane of polarized MDCK cells. Further-
more, MRP2-expressing MDCK cells and antibodies
speci¢c for the amino terminus of MRP2 were useful
in identifying the extracellular location of the amino
terminus of MRP2 [8].
In addition to the apical conjugate export pump
MRP2, hepatocytes express basolateral conjugate ex-
port pumps which have been considered to be MRP
isoforms [27,99]. Antibodies speci¢c for MRP1
showed expression of this isoform in the plasma
membrane of many di¡erent cell types [104^106]
and in the basolateral membrane of polarized epithe-
lia [107,108]. Transfection of pig kidney cells resulted
in basolateral localization of MRP1 [109]. Signi¢cant
amounts of MRP1 mRNA, however, were not de-
tected in human liver [45,49]. Instead, the isoform
MRP3 was recently cloned from liver by several
groups [33,39,110^112] and localized to the basolat-
eral membrane of human hepatocytes [33,39] and
human cholangiocytes [39] by using MRP3-speci¢c
antibodies. mRNA encoding MRP3 was also de-
tected in colon, small intestine, pancreas, prostate
and kidney [33,111,112]. It will be of interest to ana-
lyze the membrane localization of MRP3 in these
tissues. Transfection of MRP3 cDNA resulted in ba-
solateral membrane expression of this isoform in
MDCK cells (Fig. 2, [39]).
Thus, expression of proteins with similar function,
but di¡erent membrane localization in a single cell
type provides a unique tool for studying distinct sort-
ing motifs of these related proteins of the MRP fam-
ily.
5.2. MRP2-GFP construct expression in polarized
HepG2 cells
MRP2 is predominantly found in the apical mem-
brane of polarized cells; however, cholestasis, hyper-
osmotic stress, or disruption of cell junctions cause
partial redistribution of this conjugate export pump
into intracellular vesicles by endocytic retrieval
[100,113,114]. For detailed studies on this process,
visualization of intracellular transport of MRP2 pro-
vides a useful tool. Tagging of proteins with the
green £uorescent protein (GFP) has been valuable
for studies on molecular mechanisms of intracellular
protein tra⁄cking (reviewed in [115,116]). Human
hepatoma HepG2 cells polarize after several days
in culture and form apical vacuoles between adjacent
cells [117^119]. The expression pattern of MRP2, C-
terminally tagged with GFP, was completely di¡erent
from that seen for GFP alone (Fig. 2). GFP was
distributed throughout the cells, excluding the apical
vacuoles. MRP2-GFP predominantly localized to the
apical membrane which appeared as a ring-like struc-
ture along the circumference of apical vacuoles. In
addition, MRP2-GFP was associated with the mem-
brane surrounding intracellular vesicles of varying
size. Immuno£uorescence studies with antibodies
speci¢c for the amino terminus of MRP2 demon-
strated that the observed GFP £uorescence correctly
re£ected the localization of MRP2. Because of the
auto£uorescence of GFP-tagged proteins, intracellu-
lar tra⁄cking of MRP2-GFP can be visualized by
real-time video imaging. In addition, the e¡ect of
substances, such as microtubule or micro¢lament in-
hibitors on tra⁄cking can be analyzed.
5.3. Secretion of £uorescent substrates by MRP2
Fluorescent substrates are often used to analyze
MRP activity by measuring their e¥ux out of intact
cells. Anionic £uorescent dyes, such as carboxy£uo-
rescein [120] and carboxy-2P,7P-dichloro£uorescein
[121,122], have been suggested as MRP1 substrates
because the rate of dye extrusion directly correlated
with MRP1 expression levels. A similar correlation
was observed between MRP1 expression levels and
the release rate of the £uorescent Ca2 indicators
calcein [14,15] and Fluo-3 [17] from intact cells. Flu-
orescent glutathione S-conjugates, such as gluta-
thione bimane [123,124] and glutathione methyl£uo-
rescein [114], are likely transported by MRP2 as
indicated by lack of their transport in hepatocytes
from MRP2-de¢cient mutant rats. Fluo-3 has been
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Fig. 4. Exon organization of the human MRP2 gene and sites of mutations in Dubin^Johnson syndrome. The exon boundaries are
represented by vertical lines, the exon numbers are indicated, and the nucleotide-binding domains (NBD1 and NBD2) are shaded. Ar-
rows indicate the sites of mutations identi¢ed so far. H1 and H2 correspond to mutations identi¢ed in Heidelberg [53], A1 corre-
sponds to a patient analyzed in Amsterdam [96], F1^4 correspond to mutations identi¢ed in Fukuoka [132,133], and S1 indicates the
position of the mutation identi¢ed in Saga [130].
Fig. 3. Secretion of Fluo-3 into apical vacuoles of WIF-B cells and inhibition of Fluo-3 secretion by cyclosporin A and MDR1 P-gly-
coprotein inhibitors. (A) Structure of the £uorescent organic penta-anion Fluo-3 [127,128]. (B) WIF-B cells were incubated with the
non-£uorescent acetoxymethylester of Fluo-3, Fluo-3-AM, which was taken up by the cells, and hydrolyzed to the £uorescent Fluo-3.
Fluo-3 secretion into apical vacuoles was observed by £uorescence microscopy as described [16]. (C) Phase contrast micrograph corre-
sponding to B. (D^F) Quantitative analysis of inhibition of Fluo-3 secretion into apical vacuoles of WIF-B cells was performed as de-
scribed [16]. Whereas cyclosporin A inhibited Fluo-3 secretion (D), no signi¢cant inhibitory e¡ects were observed at the same concen-
trations of the non-immunosuppressive cyclosporin derivative (and MDR1 P-glycoprotein inhibitor) PSC833 (E [129]), or with the
selective MDR1 P-glycoprotein inhibitor LY335979 (F [130,131]). Scale bar: 10 Wm.
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shown to be a good substrate for MRP2 [16] and
MRP1 [18]. Substrate properties of Fluo-3 were dem-
onstrated by its ATP-dependent transport into in-
side-out membrane vesicles from normal, as opposed
to MRP2-de¢cient membrane vesicles [16]. These re-
sults indicate that MRP2 is the predominant export
pump which mediates the biliary excretion of Fluo-3.
Polarized rat hepatoma cells form apical vacuoles
between adjacent cells [125,126] and express MRP2
in the apical membrane [16]. Secretion of Fluo-3 [16]
and other £uorescent substrates into the apical vac-
uoles can be readily observed by £uorescence micros-
copy (Fig. 3). Fluo-3 transport into apical vacuoles
via MRP2 was inhibited by cyclosporin A, but not
by the same concentration of the non-immunosup-
pressive cyclosporin A analog PSC833 or by the se-
lective MDR1 P-glycoprotein inhibitor LY335979
(Fig. 3 [16]). Taken together, £uorescent anions and
£uorescent glutathione S-conjugates may serve as
useful substrates to study the function of apical
MRP2 in intact polarized cells.
Fig. 5. Expression of MRP2 and P-glycoprotein (P-Gps) in (A^C) normal and (D^F) Dubin^Johnson syndrome liver. In normal liver,
P-glycoprotein (A; green) and MRP2 (B; red) colocalize to the canalicular membrane domain, resulting in a yellow color (C). In pa-
tient H2 with Dubin^Johnson syndrome [53], immuno£uorescence microscopy reveals the complete absence of MRP2 from the hepa-
tocyte canalicular membrane as well as other membrane domains (E,F). Expression of P-glycoproteins, however, is not a¡ected in the
patient (D,F). Open arrowheads indicate the auto£uorescence of pigment granules typically observed in Dubin^Johnson syndrome liv-
er. These pigment granules do not contain MRP2 protein (scale bar in C: 10 Wm; same original magni¢cation in all panels). Repro-
duced with permission from Tsujii et al. [53].
BBAMEM 77715 19-11-99 Cyaan Magenta Geel Zwart
J. Ko«nig et al. / Biochimica et Biophysica Acta 1461 (1999) 377^394 389
6. Hereditary de¢ciency of MRP2 in Dubin^Johnson
syndrome
Mutations in the MRP2 gene, some of which are
associated with the absence of the MRP2 protein
from the hepatocyte canalicular membrane (Figs. 4
and 5), have been discovered in humans [53,96,132^
134] and rats [28,30]. The Dubin^Johnson syndrome
in humans is an autosomal recessively inherited dis-
order characterized by conjugated hyperbilirubine-
mia and pigment deposition in the liver [135^137].
The de¢cient transport of monoglucuronosyl and
bisglucuronosyl bilirubin as well as other anionic
conjugates from hepatocytes into bile is caused by
the absence of the MRP2 protein from the canalicu-
lar membrane [52,53,96,99]. So far, mutations in the
MRP2 gene leading to a functionally de¢cient pro-
tein inserted into the hepatocyte canalicular mem-
brane have not been identi¢ed. Moreover, we have
neither detected truncated MRP2 protein in the hep-
atocytes from a Dubin^Johnson syndrome patient
with a stop-codon in exon 23 nor in a patient with
a 6-nucleotide deletion in exon 30 [53]. Current
knowledge on the sites of mutations in the coding
sequence as well as in splice sites of the MRP2
gene in Dubin^Johnson syndrome together with the
exon organization of the human MRP2 gene are de-
picted in Fig. 4. Determination of the exon^intron
organization of the gene has been a prerequisite for
the elucidation of mutations underlying Dubin^John-
son syndrome [53,133]. The human MRP2 gene has
been localized to chromosome 10q23^q24 [50], it
contains 32 exons [53,133] and a high proportion
of class 0 introns [53]. The comparison with the
exon^intron organization of the human MRP1 gene
[51] displays some remarkable features. Both gene
structures exhibit pronounced similarities as indi-
cated by the number and size of the exons, by the
high proportion of class 0 introns, and by 21 identi-
cal splice junction sites on the amino acid level [53].
Despite the fact that human MRP1 and MRP2 share
only 48% amino acid sequence identity (Table 1), a
close relationship of both transporters is indicated by
their similar substrate speci¢city [8,13,40] and by
their very similar genomic organization [53].
The mutations detected until now in the MRP2
gene which are associated with Dubin^Johnson syn-
drome are scattered preferentially over the 3P-proxi-
mal half of the mRNA including the exons encoding
both nucleotide-binding domains (Fig. 4). Estab-
lished mutations include a nonsense mutation leading
to a premature termination codon [53,96], a missense
mutation a¡ecting the ¢rst nucleotide-binding do-
main [132,133], a deletion mutation leading to the
loss of two amino acids in the second nucleotide-
binding domain [53], and splice junction mutations
leading to exon deletions and premature termination
codons [132^134]. Furthermore, mutations were
identi¢ed in two well-characterized hyperbilirubine-
mic rat strains, which have been considered as ani-
mal models of the human Dubin^Johnson syndrome,
the GY/TRÿ mutant rat [28] and the Eisai hyperbi-
lirubinemic rat (EHBR) [30]. These mutations intro-
duce premature termination codons at codon 401
and 855 in GY/TR3 and EHBR mutant rats, respec-
tively. In both mutant livers, however, no truncated
proteins were detected [29] and the MRP2 mRNA
was below detectability as analyzed by Northern
blotting [28^30]. The introduction of premature ter-
mination codons leads to a decrease in the level of
some mRNAs by a mechanism termed ‘nonsense
mediated decay’ [138]. In the case of a stop-codon
5P of the last splice site, this is recognized during
translation and the mRNA is subjected to decay
[138]. It is likely that the absence of the MRP2 pro-
tein from the hepatocyte canalicular membrane, in
some cases of Dubin^Johnson syndrome [52,53,99],
is also a consequence of the rapid degradation of the
mutated mRNA. Other mutations in the MRP2 gene
may lead to a reduced stability of the protein, may
a¡ect tra⁄cking and apical localization of the pro-
tein, or may lead to a functionally de¢cient, but cor-
rectly localized, MRP2 protein.
7. Conclusions
Several members of the increasingly large MRP
family mediate the primary-active ATP-dependent
unidirectional transport of amphiphilic anions. Pro-
totypic high-a⁄nity substrates include the gluta-
thione S-conjugate leukotriene C4 and the glucuro-
nosides bisglucuronosyl bilirubin and 17L-
glucuronosyl estradiol. The human isoforms MRP1,
MRP2, and MRP3 di¡er by their kinetic properties,
by their domain-speci¢c sorting and localization to
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the plasma membrane, and by the regulation of their
expression. Mutations in the human MRP2 gene en-
coding the apical isoform have been identi¢ed which
cause the absence of the MRP2 protein from the
hepatocyte canalicular membrane and the conjugated
hyperbilirubinemia of Dubin^Johnson syndrome.
Expression of recombinant MRP2 at high levels
has provided direct evidence that the apical isoform
confers resistance to several chemotherapeutic agents
including cisplatin. Elucidation of the function and
localization of di¡erent MRP isoforms has contrib-
uted to our understanding of the role of these con-
jugate export pumps in terminal excretion of xeno-
biotic and endogenous substances, in detoxi¢cation,
in chemoprevention, and in drug resistance.
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